Aarti Pharmalabs Ltd
AARTIPHARMAarti Pharmalabs Ltd
AARTIPHARM
Price Chart
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 25.23 | 3.28 | 0.47% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 49.70 | 6.31 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Aarti Pharmalabs Limited is a manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), and xanthine derivatives situated in India. The Company delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, Bosutinib Intermediate and others. Its xanthine and allied products include theophylline anhydrous, aminophylline, etophylline, and theophylline.
Peers
Compare with peersDivi's Laboratories Ltd
Syngene International Ltd
Dishman Carbogen Amcis Ltd
Vimta Labs Ltd
Brooks Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 1,202.45 | 1,947.55 | 1,857.51 | 1,978.10 | |||||
Raw Materials | 0.00 | 686.72 | 1,295.12 | 1,040.67 | 1,564.65 | |||||
| Power & Fuel Cost | 44.14 | 75.10 | 84.03 | |||||||
| Employee Cost | 85.20 | 121.32 | 128.03 | |||||||
| Selling & Administrative Expenses | 27.35 | 110.28 | 97.65 | |||||||
| Operating & Other expenses | 149.58 | 1.37 | 116.19 | |||||||
EBITDA | 0.00 | 209.46 | 344.36 | 390.94 | 413.45 | |||||
| Depreciation/Amortization | 0.00 | 42.12 | 62.54 | 73.24 | 78.94 | |||||
| PBIT | 0.00 | 167.34 | 281.82 | 317.70 | 334.51 | |||||
| Interest & Other Items | 0.00 | 11.96 | 21.05 | 17.21 | 19.50 | |||||
| PBT | 0.00 | 155.38 | 260.77 | 300.49 | 315.01 | |||||
| Taxes & Other Items | 0.00 | 33.13 | 67.28 | 83.59 | 86.93 | |||||
| Net Income | 0.00 | 122.25 | 193.49 | 216.90 | 228.08 | |||||
| EPS | 0.00 | 4,890.00 | 42.58 | 23.93 | 25.17 | |||||
| DPS | 0.00 | 0.00 | 2.00 | 3.00 | 3.00 | |||||
| Payout ratio | — | 0.00 | 0.05 | 0.13 | 0.12 |
Company Updates
Peers & Comparison
Health CareLabs & Life Sciences Services
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Aarti Pharmalabs Ltd | 26.54 | 3.28 | 0.47% |
| Divi's Laboratories Ltd | 97.90 | 11.54 | 0.51% |
| Syngene International Ltd | 66.93 | 8.02 | 0.15% |
| Dishman Carbogen Amcis Ltd | -22.48 | 0.61 | — |
Price Comparison
Compare AARTIPHARM with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Aarti Pharmalabs Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
Quant Small Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.2028% | Percentage of the fund’s portfolio invested in the stock 0.26% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 80/94 (-5) |
Quant Flexi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.0853% | Percentage of the fund’s portfolio invested in the stock 0.79% | Change in the portfolio weight of the stock over the last 3 months 0.17% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 32/46 (-2) |
HDFC Multi Cap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.4765% | Percentage of the fund’s portfolio invested in the stock 0.16% | Change in the portfolio weight of the stock over the last 3 months 0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 161/218 (+3) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateJul 31, 2024
Dividend/Share
₹1.00
Ex DateEx Date
Jul 31, 2024
Cash Dividend
Ex DateEx DateFeb 16, 2024
Dividend/Share
₹2.00
Ex DateEx Date
Feb 16, 2024
Net profit of Aarti Pharmalabs rose 5.44% to Rs 54.62 crore in the quarter ended September 2024 as against Rs 51.80 crore during the previous quarter ended September 2023. Sales rose 4.15% to Rs 458.03 crore in the quarter ended September 2024 as against Rs 439.80 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales458.03439.80 4 OPM %20.4520.01 - PBDT92.6585.08 9 PBT71.7766.94 7 NP54.6251.80 5 Powered by Capital Market - Live
Aarti Pharmalabs has announced that Mr. Nikhil Natu has tendered his resignation from the position of Company Secretary & Compliance Officer of the Company and has been relieved from his duties effective closing of business hours on 30 October 2024.Powered by Capital Market - Live
Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live
Net profit of Aarti Pharmalabs rose 17.75% to Rs 55.45 crore in the quarter ended June 2024 as against Rs 47.09 crore during the previous quarter ended June 2023. Sales rose 21.19% to Rs 555.49 crore in the quarter ended June 2024 as against Rs 458.36 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales555.49458.36 21 OPM %17.3618.52 - PBDT93.8481.18 16 PBT73.6863.98 15 NP55.4547.09 18 Powered by Capital Market - Live
Aarti Pharmalabs will hold a meeting of the Board of Directors of the Company on 5 August 2024.Powered by Capital Market - Live
Chennai Petroleum Corporation Ltd leads losers in ‘A’ group
Aarti Pharmalabs announced that the 91th Annual General Meeting (AGM) of the company will be held on 7 August 2024.Powered by Capital Market - Live
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant